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Background. Matrix metalloproteinases (MMPs) and myeloperoxidase (MPO) contribute to the inﬂammatory cascade in the
cerebrospinal ﬂuid (CSF) during bacterial meningitis. We determined levels of MPO, MMP-8, MMP-9, and tissue inhibitor of
metalloproteinase- (TIMP-) 1 in the CSF of children with bacterial meningitis and investigated how these inﬂammatory
mediators relate to each other and to the disease outcomes. Methods. Clinical data and the diagnostic CSF samples from 245
children (median age eight months) with bacterial meningitis were obtained from a clinical trial in Latin America in 1996–
2003. MMP-9 levels in the CSF were assessed by zymography, while MMP-8, MPO, and TIMP-1 concentrations were
determined with immunoﬂuorometric and enzyme-linked immunosorbent assays. Results. MPO correlated positively with
MMP-8 (rho 0.496, P < 0:001) and MMP-9 (rho 0.153, P = 0:02) but negatively with TIMP-1 (rho -0.361, P < 0:001). MMP-8
emerged as the best predictor of disease outcomes: a CSF MMP-8 concentration above the median increased the odds of death
4.9-fold (95% conﬁdence interval 1.8–12.9). Conclusions. CSF MMP-8 presented as an attractive prognostic marker in children
with bacterial meningitis.
1. Introduction
Bacterial meningitis (BM) remains a signiﬁcant cause of
childhood mortality and morbidity globally, often aﬀecting
children in developing, resource-poor countries [1]. Invading
bacteria trigger a strong host reaction, which is observed in
the cerebrospinal ﬂuid (CSF) as the release of proinﬂamma-
tory mediators [2]. The current understanding is that this
intense proinﬂammatory cascade at least in part accounts
for poor outcomes, so common in BM [2].
Matrix metalloproteinases (MMPs) are a structurally
related but genetically distinct group of proteolytic enzymes
which play a central role in regulating tissue destruction,
remodeling, and immune responses, including in BM [3–5].
Within this proteinase group, marked diﬀerences exist in
terms of expression: inductive MMPs are upregulated in
inﬂammatory conditions, while others are rather consistently
expressed [6, 7]. The activities of MMPs are further regulated
by means of compartmentalization, as well as secretion as
inactive zymogens requiring activation before being catalyti-
cally competent. Finally, active MMPs may be inhibited by
tissue inhibitors of metalloproteinases (TIMPs), acting as
their endogenous regulators [8].
The proinﬂammatory burden in the CSF during BM
induces the production of reactive oxygen species, catalyzed
by the enzyme myeloperoxidase (MPO), among others.
Hindawi
Mediators of Inﬂammation
Volume 2019, Article ID 7436932, 8 pages
https://doi.org/10.1155/2019/7436932
Interestingly, in addition to targeting microbes, MPO is capa-
ble of both oxidatively activating latent pro-MMPs and inac-
tivating TIMPs [9, 10]. Thus, MPO serves as a link between
the oxidative burst and the proteolytic web of MMPs. In fact,
the potential of reactive oxygen species to activate MMPs has
been suggested a possible target for adjuvant treatment in
BM [11].
In a previous study, our group showed that CSF MMP-9
is strongly upregulated in BM and that increased MMP-9
levels on admission associate with severe disease and an
increased risk of death [12]. The release of MMP-8 is also
upregulated in BM [13, 14], but no correlation with outcome
has been found [13].
To our knowledge, however, no previous studies have
explored the relation between these inﬂammatory mediators
in a clinical setting. By measuring the MMP-8, MMP-9,
TIMP-1, and MPO levels in the CSF of children with BM,
we addressed two questions in this study: First, how would
these inﬂammatory mediators relate to each other in human
subjects? Second, to what extent would the results reﬂect the
outcomes of this severe disease?
2. Materials and Methods
2.1. Patient Data. This study was a retrospective analysis
using the prospectively collected data from a large double-
blind treatment trial on childhood BM in Latin America in
1996–2003 [15]. The details of the study setup are described
elsewhere [15], but in short, all children aged 2 months to 16
years received ceftriaxone for 7–10 days. In addition, the
patients were randomized to receive either dexamethasone
intravenously, glycerol orally, both agents, or only placebo
as adjuvant treatment. CSF samples were collected on admis-
sion and after primary analyses frozen for later use. The study
protocol was approved by all the local ethics committees. For
this study, we included the patients from whom a frozen CSF
sample was available.
On arrival at the hospital, the patients’ clinical condition
was graded using the age-adjusted Glasgow Coma Scale
(GCS). Besides death, the disease outcomes were registered
by deﬁning as “severe neurological sequelae” all cases of blind-
ness, quadriplegia, severe psychomotor retardation, or hydro-
cephalus requiring a shunt. “Any neurological sequelae” also
comprised milder deﬁcits such as ataxia and hemiparesis.
2.2. Immunoﬂuorometry. Concentrations of MMP-8 were
determined with a time-resolved immunoﬂuorometric assay
(Medix Biochemica, Espoo, Finland). The monoclonal
MMP-8-speciﬁc antibodies 8708 and 8706 were used as a
catching antibody and a tracer antibody, respectively. The
tracer antibody was labeled using a europium chelate. The
assay buﬀer contained 20mM Tris-HCl, pH 7.5, 0.5M NaCl,
5mM CaCl2, 50 μM ZnCl2, 0.5% bovine serum albumin,
0.05% sodium azide, and 20mg/L diethylenetriaminepenta-
acetic acid. Samples were diluted in assay buﬀer and incu-
bated for 1 h, followed by incubation for 1 h with tracer anti-
body. Enhancement solution was added, and after 5min,
ﬂuorescence was measured using a 1234 Delﬁa Fluorometer
(Wallac, Turku, Finland). The interassay coeﬃcient of varia-
tion was 7.3%, and the detection limit for the assay was
0.08 ng/mL.
2.3. Enzyme-Linked Immunosorbent Assays (ELISAs). The
levels of MPO and TIMP-1 were determined using com-
mercially available ELISA kits. MPO ELISA (Immundiag-
nostik AG, Bensheim, Germany) and the Amersham Tissue
Inhibitor of Metalloproteinases-1 (TIMP-1) Human Biotrak
ELISA systems (Amersham Biosciences, GE Healthcare,
Buckinghamshire, UK) were used according to the manufac-
turer’s instructions. The secondary antibody in each kit was
conjugated with horseradish peroxidase, and tetramethyl-
benzidine was used as a substrate. The absorbance was
measured at 450nm using a Victor X4 Multilabel Reader
(PerkinElmer Finland Oy, Turku, Finland). The interassay
coeﬃcient of variation was <3% for MPO and <12% for
TIMP-1, while the corresponding detection limits were
0.294 ng/mL and 1.25 ng/mL [16]. The levels of MMP-8
and TIMP-1 were expressed as ng/mL, and for calculation
of the MMP-8/TIMP-1 molar ratios, the levels were con-
verted to mol/L [17, 18].
2.4. Gelatin Zymography. The MMP-9 levels were assayed
using zymography 11% sodium dodecyl sulphate-
polyacrylamide gels, based on modiﬁcation of the method
of Lindberg et al. [14]. Our zymography gels were impreg-
nated with 1mg/mL gelatin as the substrate. Brieﬂy, after
2 h preincubation with Laemmli’s sample buﬀer without
any reducing reagents, electrophoresis was performed.
Thereafter, the gels were washed for 30min twice with
50mM Tris-HCl buﬀer solutions, pH 7.5, containing 2.5%
Tween 80 and 0.02% NaN3; in addition, the second wash
was supplemented with 0.5mM CaCl2 and 1 μM ZnCl2.
Finally, the gels were incubated in 50mM Tris-HCl buﬀer,
pH 7.5, containing 0.02% NaN3, 0.5mM CaCl2, and 1μM
ZnCl2 but no Tween 80, overnight at 37
°C. The gels were
then stained with 1% Coomassie Brilliant Blue R-250, and
the gelatinolytic activity was visualized as clear bands against
the blue background on stained gels [19]. The intensities of
gelatinolytic activity were evaluated with a Bio-Rad Model
GS-700 Imaging Densitometer using the Bio-Rad Quantity
One program (Bio-Rad Laboratories, Hercules, CA, USA)
[14]. The molecular forms of MMP-9 were conﬁrmed with
speciﬁc anti-antibodies for MMP-9 (Calbiochem, Merck
KGaA, Darmstadt, Germany) by the western blot method.
The total level of MMP-9 was deﬁned as the combined gela-
tinolytic activity of actMMP-9 and proMMP-9. The percen-
tual expression of the activated form of MMP-9 (Act% of
MMP-9) based on densitometric evaluation was calculated
as actMMP‐9/ðproMMP‐9 + actMMP‐9Þ [20].
2.5. Statistical Analysis. Normality of the measured variables
was visually inspected. Associations with continuous patient
characteristics, as well as interactions between the variables,
were assessed using Spearman’s rank correlation, while the
relation to categorical patient characteristics was analyzed
using the Mann-Whitney U test or the Kruskal-Wallis test.
The Bonferroni correction was applied in multiple compari-
sons, and P values < 0.05 were considered signiﬁcant.
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The predictive values of the studied variables were deter-
mined by binary logistic regression analysis. To facilitate the
interpretation of the results, regression analyses were con-
ducted using median-cut values of the variables. The odds
ratios for death, death or severe neurological sequelae, and
death or any neurological sequelae of all the studied mole-
cules were adjusted for the level of consciousness on admis-
sion. This was done due to the pivotal impact of the child’s
presenting status on the outcomes of BM [21]. Local regres-
sion was applied to visually estimate the risk of death for dif-
ferent values of MMP-8.
Statistical analyses were conducted with IBM SPSS
Statistics software, version 24 (IBM Corp., NY, US), except
for the local regression procedure which was performed in
R, version 3.4.2 (R Foundation for Statistical Computing,
Vienna, Austria).
3. Results
3.1. Study Group. This series comprised 245 children with
bacterial meningitis originating from the Dominican Repub-
lic (n = 104), Venezuela (n = 54), Paraguay (n = 51), and
Ecuador (n = 36). Scarcity of CSF allowed the MMP-9 mea-
surements from 240, MMP-8 from 236, and TIMP-1 and
MPO from 232 patients. The patient characteristics, causa-
tive agents, and disease outcomes are summarized in Table 1.
3.2. Median Values and Associations with Baseline Patient
Characteristics. The expression rates in the CSF for MMP-
8, TIMP-1, MPO, proform of MMP-9 (proMMP-9), and
active form of MMP-9 (actMMP-9) were 99%, 94%, 84%,
93%, and 73%, respectively. The median concentrations were
453ng/mL (interquartile range (IQR) 189–1,593 ng/mL)
for MMP-8, 232ng/mL (IQR 53–1,251) for TIMP-1, and
5,018 ng/mL (1,993–16,927) for MPO. The corresponding
median densitometric values were 0.21 (IQR 0.00–0.78) for
actMMP-9, 0.42 (IQR 0.14–1.46) for proMMP-9, and 0.64
(IQR 0.16–2.21) for total MMP-9 activity (Figure 1).
While comparing the CSF MMP levels with the baseline
patient characteristics, some diﬀerences between MMP-9
and MMP-8 were noted. First, total MMP-9 correlated with
the patient’s presenting condition: the worse the GCS score,
the higher the MMP-9 level (Table 2). In contrast, a similar
association was not detected for MMP-8. Second, the
MMP-8 concentrations correlated with the CSF white cell
count, CSF protein, and CSF glucose levels, while no such
correlations were found for total MMP-9 (Table 2). Finally,
the duration of preadmission illness associated with the levels
of total MMP-9, although not with MMP-8 (Table 2).
MPO correlated, similarly to total MMP-9, negatively with
the GCS score on admission but was also positively associated
with the CSF white cell count and protein level. In contrast,
TIMP-1 associated inversely with these CSF parameters. The
relation of TIMP-1 to the GCS score on admission mimicked
that of total MMP-9 and MPO (Table 2). Moreover, TIMP-1
was the only variable relating to patient age: the younger the
patient, the higher the CSF TIMP-1 concentration.
Of all the examined variables, only MMP-9 distinguished
between the diﬀerent causative agents (P = 0:006). Strepto-
coccus pneumoniae meningitis induced the highest MMP-9
levels, although the only signiﬁcant diﬀerence was found
between meningitides caused by S. pneumoniae and Hae-
mophilus inﬂuenzae (P = 0:001).
3.3. Associations between the Studied Molecules.A correlation
matrix for the studied variables is presented in Table 3. MPO
correlated positively with MMP-8, with the molar ratio of
MMP-8 to TIMP-1, and with total MMP-9. In contrast, the
higher the MPO concentration, the lower that of TIMP-1.
The concentration of TIMP-1 related negatively to the per-
centage of active MMP-9; however, such a negative correla-
tion was not noted with MMP-8 or with total MMP-9.
High levels of MMP-8 related to higher total MMP-9, but
not to a higher percentage of active MMP-9.
Table 1: Patient characteristics.
Characteristic Result
Total number of patients 245
Male sex (%) 140/245 (57.1)
Age, median months (IQR) 8 (5–19)
Duration of preadmission illness,
median days (IQR)
2 (1–3)
GCS score on admission, median (IQR) 13 (11–14)
Etiology, number of cases (%)
Haemophilus inﬂuenzae 122 (49.8)
Streptococcus pneumoniae 64 (26.1)
Neisseria meningitidis 10 (4.1)
Other 12 (4.9)
Unknown 37 (15.1)
CSF test results on admission
Leukocyte count, median cells/μL (IQR) 2,500 (900–8,050)
Protein level, median mg/dL (IQR) 158 (94–257)
Glucose level, median mg/dL (IQR) 15 (6–32)
Disease outcomes, number of patients
Death (%) 33/245 (13.5)
Death or severe neurological sequelae (%) 58/242a (24.0)
Death or any neurological sequelae (%) 112/241b (46.5)
IQR: interquartile range. aInformation on severe neurological sequelae was
missing for 3 patients. bInformation on any neurological sequelae was
missing for 4 patients.
1
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Figure 1: Gelatin zymography analysis of meningitis cerebrospinal
ﬂuid (CSF). (a) Lanes 1-3 represent CSF with elevated levels of
MMP-9, and lanes 4-6 represent CSF with low levels of MMP-9.
(b) Lanes 1 and 2 represent western immunoblot analysis of
MMP-9. Mobilities of 92 kDa pro MMP-9 (proMMP-9) and active
MMP-9 (actMMP-9) species are indicated on the right.
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3.4. Relation to Disease Outcomes. The crude and adjusted
odds ratios (ORs) and 95% conﬁdence intervals (CIs) for
death and for the composite outcomes of death and severe
or any neurological sequelae are presented in Tables 4(a)–
4(c), respectively. Notably, MMP-8 emerged as the best pre-
dictor of demise; even when adjusted for the presenting con-
dition, a CSF concentration above the median increased the
odds of death almost ﬁvefold (OR 4.9, 95% CI 1.8–12.9).
Figure 2 shows the risk of death versus diﬀerent values of
MMP-8. A less clear relationship was found between the
molar ratio of MMP-8 to TIMP-1 and the odds of death
(adjusted OR 2.8, 95% CI 1.2–7.0). None of the other vari-
ables was independent predictors of death after adjustment
(Table 4(a)).
When neurological deﬁcits were included in the calcula-
tions, the results remained similar. For death or severe neu-
rological sequelae, the adjusted OR for median-cut MMP-8
was 2.3 (95% CI 1.2–4.6); for death or any neurological
sequelae, the equivalent OR was 2.2 (95% CI 1.2–4.0)
(Tables 4(b) and 4(c)).
A CSF MPO concentration above the median doubled
the odds of death or severe neurological sequelae (OR 2.2,
95% CI 1.1–4.4). However, it did not increase the odds of
death or any neurological sequelae. Adjusted median-cut
values for CSF MMP-9, TIMP-1, or the molar ratio of
MMP-8 and TIMP-1 did not predict worse composite out-
comes (Tables 4(b) and 4(c)).
4. Discussion
Our results suggest that elevated MMP-8 levels in the CSF of
children with BM predict poor disease outcomes, especially
Table 2: Associations between MMP-8, MPO, TIMP-1, and MMP-9 and baseline patient characteristicsa.
Characteristic MMP-8 MPO TIMP-1 Total MMP-9
Age
ρ 0.071 ρ -0.013 ρ -0.173 ρ 0.009
P = 0:28 P = 0:84 P = 0:009 P = 0:89
Duration of preadmission illness in days
ρ -0.057 ρ -0.182 ρ 0.161 ρ 0.242
P = 0:55 P = 0:05 P = 0:09 P = 0:008
GCS on admission
ρ -0.074 ρ -0.179 ρ -0.135 ρ -0.258
P = 0:27 P = 0:007 P = 0:04 P < 0:001
CSF test results
CSF white cell count
ρ 0.356 ρ 0.238 ρ -0.275 ρ -0.019
P < 0:001 P = 0:001 P < 0:001 P = 0:79
CSF protein level
ρ 0.350 ρ 0.440 ρ -0.189 ρ 0.041
P < 0:001 P < 0:001 P = 0:007 P = 0:56
CSF glucose
ρ -0.219 ρ -0.198 ρ -0.050 ρ 0.090
P = 0:001 P = 0:004 P = 0:46 P = 0:18
aAssociations were calculated using Spearman’s rank correlation. Signiﬁcant correlations are in bold.
Table 3: Correlation matrix for the studied moleculesa.
Variable MPO MMP-8 TIMP-1
Total
MMP-9
Act% of
MMP-9
MMP8/TIMP-1
molar ratio
MPO N/A
ρ 0.496 ρ -0.361 ρ 0.153 ρ 0.128 ρ 0.528
P < 0:001 P < 0:001 P = 0:02 P = 0:05 P < 0:001
MMP-8
ρ 0.496
N/A
ρ -0.052 ρ 0.160 ρ 0.051 ρ 0.556
P < 0:001 P = 0:43 P = 0:02 P = 0:44 P < 0:001
TIMP-1
ρ -0.361 ρ -0.052
N/A
ρ -0.052 ρ -0.158 ρ -0.476
P < 0:001 P = 0:43 P = 0:44 P = 0:02 P < 0:001
Total MMP-9
ρ 0.153 ρ 0.160 ρ -0.052
N/A
ρ 0.570 ρ 0.186
P = 0:02 P = 0:02 P = 0:44 P < 0:001 P = 0:005
Act% of MMP-9
ρ 0.128 ρ 0.051 ρ -0.158 ρ 0.570
N/A
ρ 0.108
P = 0:05 P = 0:44 P = 0:02 P < 0:001 P = 0:10
MMP8/TIMP-1 molar ratio
ρ 0.528 ρ 0.556 ρ -0.476 ρ 0.186 ρ 0.108
N/A
P < 0:001 P < 0:001 P < 0:001 P = 0:005 P = 0:10
aCorrelations were calculated using Spearman’s rank correlation. Signiﬁcant correlations are in bold. Act% of MMP-9 represents the percentual expression of
the active form of MMP-9.
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an increased risk of death. Furthermore, we demonstrated
that the actions of MPO, MMP-8, and MMP-9 during the
proinﬂammatory burst of BM run parallel to each other,
counterbalanced by TIMP-1.
Prior data on these issues are sparse. A few studies have
registered upregulation of MMP-8 in CSF [13, 14], but no
association with disease outcomes has been reported [13].
The rather small sample sizes in those analyses probably con-
cealed the ﬁndings we observed here, although also diﬀerent
statistical methods were applied.
Previous data suggest that MPO can oxidatively modify
the function of MMP-8, MMP-9, and TIMP-1 [9–11, 22].
The positive association of MPO with MMP-8 and MMP-9
in our study might demonstrate such an interplay between
these mediators or simply indicate that these enzymes share
a common origin or a factor that leads to upregulation.
Similarly, the negative relation of MPO to TIMP-1 could
reﬂect the inactivation of TIMP-1 by MPO products [9],
which would further strengthen the proinﬂammatory burden
and favor the enhanced proteolytic actions of MMPs. Our
results do not, however, show causality between MPO and
the studied MMPs and TIMP-1 and thus leave the deﬁni-
tive relationship between these CSF inﬂammatory mediators
unclear. Indeed, MPO and these MMPs are probably upreg-
ulated through similar pathways involving enhanced neutro-
phil degranulation during inﬂammation, while the expression
of TIMP-1 seems substantially diﬀerent [23].
The comparison of the MMP concentrations with the
other CSF parameters revealed that MMP-8 related to the
CSF white cell count, while MMP-9 did not. The contradic-
tory results of previous studies suggest that CSF pleocytosis
is merely one of several factors aﬀecting the amount of
MMPs in the CSF [12–14, 24]. As presynthetized and pre-
packed MMP-8 and MMP-9 are stored in diﬀerent subcellu-
lar granules in neutrophils, their selective degranulation
could partly account for the diﬀerences—certain conditions,
proinﬂammatory mediators, and/or microbial virulence fac-
tors might regulate and promote the degranulation of a spe-
ciﬁc enzyme [22, 25].
MMP-8 and MMP-9 diﬀered in terms of correlation with
the patient’s presenting condition. Consistent with our previ-
ous study [12], the lower the patient performed in the GCS,
Table 4
(a) Odds ratios for deatha
Variable Unadjusted OR (95% CI) P value Adjusted ORb (95% CI) P value
MMP-8 5.3 (2.1–13.4) <0.001 4.9 (1.8–12.9) 0.001
MPO 2.8 (1.2–6.3) 0.02 2.0 (0.8–4.8) 0.12
Total MMP-9 2.2 (1.0–4.8) 0.04 1.4 (0.6–3.3) 0.41
TIMP-1 0.7 (0.3–1.5) 0.34 0.7 (0.3–1.6) 0.37
MMP-8/TIMP-1 molar ratio 3.3 (1.4–7.8) 0.005 2.8 (1.2–7.0) 0.02
aThe results were obtained with binary logistic regression analysis. The ORs were calculated for cerebrospinal ﬂuid concentrations above the median. bAdjusted
for the clinical condition on admission.
(b) Odds ratios for death or severe neurological sequelaea
Variable Unadjusted OR (95% CI) P value Adjusted ORb (95% CI) P value
MMP-8 2.5 (1.3–4.6) 0.005 2.3 (1.2–4.6) 0.02
MPO 2.8 (1.4–5.2) 0.002 2.2 (1.1–4.4) 0.03
Total MMP-9 1.5 (0.8–2.7) 0.21 0.9 (0.5–1.8) 0.78
TIMP-1 0.8 (0.4–1.5) 0.51 0.8 (0.4–1.5) 0.46
MMP-8/TIMP-1 molar ratio 1.5 (0.8–2.8) 0.20 1.3 (0.6–2.5) 0.50
aThe results were obtained with binary logistic regression analysis. The ORs were calculated for cerebrospinal ﬂuid concentrations above the median. bAdjusted
for the clinical condition on admission.
(c) Odds ratios for death or any neurological sequelaea
Variable Unadjusted OR (95% CI) P value Adjusted ORb (95% CI) P value
MMP-8 2.2 (1.3–3.8) 0.003 2.2 (1.2–4.0) 0.007
MPO 1.8 (1.1–3.1) 0.02 1.6 (0.9–2.8) 0.12
Total MMP-9 1.8 (1.1–3.0) 0.03 1.2 (0.7–2.2) 0.47
TIMP-1 1.4 (0.8–2.3) 0.24 1.2 (0.7–2.2) 0.45
MMP-8/TIMP-1 molar ratio 1.2 (0.7–2.0) 0.49 1.1 (0.6–2.0) 0.70
aThe results were obtained with binary logistic regression analysis. The ORs were calculated for cerebrospinal ﬂuid concentrations above the median. bAdjusted
for the clinical condition on admission.
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the higher the MMP-9 level in CSF. No such relation was
detected for MMP-8. Considering that the regulation of these
enzymes diﬀers in terms of cellular gene expression and
degranulation [6–8, 22], we reason that this diﬀerence might,
at least partially, be explained by dynamics. In line with this,
the duration of preadmission illness associated with CSF
MMP-9, but not with MMP-8.
We acknowledge limitations in our study. Due to
increased vaccination against H. inﬂuenzae, the etiology of
BM in children has dramatically changed since the collection
of the patient cohort. While the MMP-9 level indeed diﬀered
between the causative bacteria, no such diﬀerences were
detected for MMP-8 or MPO, suggesting that other factors
than bacterial etiology may be more important in regulating
the expression of these enzymes. However, also the use of
zymography as a semiquantitative method complicates the
comparison of MMP-9 with the other inﬂammatory media-
tors. The CSF samples had been kept frozen for a long time
before these analyses. Our data does not point towards degra-
dation or inactivation of these molecules during storage,
although this possibility cannot be fully excluded. Our main
ﬁnding of MMP-8 predicting poor disease outcomes was,
however, related to the median value of all samples and not
to the absolute concentration in the CSF. Finally, our clinical
study does not clarify the pathways triggered by MMP-8 that
would explain for the higher risk of poor outcomes. Based on
previous data, we hypothesize that both damaging the blood-
brain barrier and enhancing the local inﬂammation contrib-
ute to this observation.
In conclusion, CSF MMP-8 presents as an attractive
prognostic marker for BM in children. Our results, however,
warrant a prospective study with a control group to validate
these ﬁndings and to further elucidate the potential of this
molecule, for example, in the diﬀerential diagnosis of menin-
gitis. Rapid quantitative point-of-care tests for MMP-8 in
salivary/body ﬂuids are already available [26, 27].
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